United States · FDA National Drug Code directory
BOOSTRIX
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 58160-842_0ef1de88-4647-4f2d-a6cf-01777f9ccb17
- Product NDC
- 58160-842
- Form
- SUSPENSION
- Composition / generic term
- Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed
- Labeler
- GlaxoSmithKline Biologicals SA
- Marketing category
- BLA
- Marketing start / end (source format)
- 20090724
- Source listing expiry
- 20271231
Source-listed ingredients
- CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) — 5 [iU]/.5mL
- CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) — 2.5 [iU]/.5mL
- BORDETELLA PERTUSSIS TOXOID ANTIGEN (FORMALDEHYDE, GLUTARALDEHYDE INACTIVATED) — 8 ug/.5mL
- BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) — 8 ug/.5mL
- BORDETELLA PERTUSSIS PERTACTIN ANTIGEN (FORMALDEHYDE INACTIVATED) — 2.5 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 SYRINGE in 1 CARTON (58160-842-52) / .5 mL in 1 SYRINGE (58160-842-43) · 58160-842-52
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →